AERS Database Cannot Determine Adverse Event Incidence, FDA Says In Rejecting Statin Label Warning
Executive Summary
FDA denies Public Citizen’s 2001 petition requesting a black box warning about the risk of rhabdomyolysis on cholesterol-lowering drug labels, says Baycol and high-dose simvastatin are outliers.